[ad_1]
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support
Abiomed (NASDAQ:ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients. Data from a subgroup analysis of 93 non-Caucasian high- risk PCI patients enrolled in the PROTECT II Randomized Controlled Trial (RCT) finds those who were treated with Abiomed’s Impella heart pump had significantly improved clinical outcomes compared to those who were treated with the intra-aortic balloon pump (IABP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221025005193/en/
Figure 1 (Graphic: Business Wire)
Specifically, the analysis found, when compared to patients who received IABP, Impella patients experienced:
-
A 48% reduction in major adverse events (MAE), the primary endpoint of the PROTECT II RCT, out to 90 days post-procedure. (p=0.018) (see figure 1)
-
A 60% reduction in major adverse cardiac and cerebral events (MACCE) out to 90 days post-procedure. (p=0.032) (see figure 2)
-
A 75% reduction in irreversible events (death, stroke, myocardial infarction) from discharge to 90 days post-procedure. (p=0.044) (see figure 3)
The analysis of this subset population was pre-specified in the statistical analysis plan for the MAE primary endpoint of the PROTECT II …
Full story available on Benzinga.com
[ad_2]
Source link
